Armistice Capital LLC Purchases Shares of 200,000 Scholar Rock Holding Corporation $SRRK

Armistice Capital LLC acquired a new stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 200,000 shares of the company’s stock, valued at approximately $8,810,000.

Several other institutional investors also recently modified their holdings of SRRK. AQR Capital Management LLC raised its holdings in shares of Scholar Rock by 609.3% in the 1st quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock valued at $1,842,000 after purchasing an additional 49,217 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Scholar Rock by 12.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock worth $1,709,000 after purchasing an additional 5,831 shares during the period. Millennium Management LLC increased its position in Scholar Rock by 37.4% during the first quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock worth $6,438,000 after buying an additional 54,555 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Scholar Rock by 25.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock valued at $5,460,000 after buying an additional 34,594 shares during the period. Finally, Strs Ohio bought a new stake in Scholar Rock in the first quarter valued at approximately $77,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on SRRK. Piper Sandler boosted their target price on Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a report on Wednesday, March 4th. HC Wainwright lifted their target price on shares of Scholar Rock from $58.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Barclays increased their price target on shares of Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Raymond James Financial restated a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday, March 3rd. Finally, Canaccord Genuity Group started coverage on Scholar Rock in a research report on Monday, April 20th. They issued a “buy” rating and a $62.00 target price on the stock. Four analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Scholar Rock currently has a consensus rating of “Buy” and an average target price of $56.00.

Insider Buying and Selling at Scholar Rock

In other Scholar Rock news, CEO David Hallal sold 30,615 shares of Scholar Rock stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total value of $1,517,585.55. Following the completion of the transaction, the chief executive officer directly owned 1,639,034 shares of the company’s stock, valued at $81,246,915.38. The trade was a 1.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Vikas Sinha sold 10,410 shares of the company’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total value of $516,023.70. Following the sale, the chief financial officer owned 619,856 shares of the company’s stock, valued at approximately $30,726,261.92. The trade was a 1.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 63,491 shares of company stock valued at $3,147,249 in the last three months. Corporate insiders own 13.30% of the company’s stock.

Scholar Rock Trading Up 3.1%

Shares of Scholar Rock stock opened at $46.95 on Thursday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 8.64 and a current ratio of 8.64. The firm has a 50-day moving average of $47.67 and a 200-day moving average of $45.93. Scholar Rock Holding Corporation has a 52-week low of $27.07 and a 52-week high of $52.19. The stock has a market cap of $5.63 billion, a PE ratio of -13.08 and a beta of 0.69.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same period last year, the business posted ($0.67) EPS. As a group, sell-side analysts forecast that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).